Acquisition (Details) $ / shares in Units, $ in Thousands		12 Months Ended
	Oct. 10, 2023 USD ($) Right $ / shares shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Assets acquired
Cash and cash equivalents		$ 311,660	$ 243,784
Deferred tax asset		144,162	85,943
Restricted cash		270	750
TOTAL ASSETS		811,448	673,870
Liabilities assumed
Accounts payable		17,730	3,786
Other current liabilities		7,810	1,624
TOTAL LIABILITIES		344,456	271,032
Net loss		128,853	181,468	$ 34,597
Revenue		582,022	437,855	$ 305,440
Zynerba Acquisition
ACQUISITION
Cash consideration per Common Stock | $ / shares	$ 1.1059
Number of contingent value right per Common Stock | Right	1
Contingent consideration per Common Stock | $ / shares	$ 2.5444
Aggregate consideration	$ 60,000
Total purchase consideration
Cash consideration paid to selling shareholders	55,960
Cash consideration paid to settle restricted stock awards ("RSAs") as stock options	4,040
Transaction costs	2,645
Total purchase consideration	$ 62,645
Number of shares considered for determination of payments made to selling shareholders | shares	50,602,656
Price per share considered for determination of payments made to selling shareholders | $ / shares	$ 1.1059
Number of shares considered for determination of payments made to settle restricted stock awards ("RSAs") as stock options | shares	4,000,169
Price per share considered for determination of payments made to settle restricted stock awards ("RSAs") as stock options | $ / shares	$ 1.1059
Charge related to acquired in-process research and development		2,260
Assets acquired
Cash and cash equivalents	$ 25,658
Prepaid expenses and other current assets	3,540
Deferred tax asset	44,800
Restricted cash	20
Acquired in-process research and development	2,260
TOTAL ASSETS	76,278
Liabilities assumed
Accounts payable	4,995
Accrued expenses and accrued compensation	8,479
Other current liabilities	159
TOTAL LIABILITIES	13,633
Net assets acquired	$ 62,645
Severance charges		7,544
Net loss		(14,451)
Revenue		0
Unaudited pro forma net income		108,350	135,567
Unaudited pro forma net product revenue		0	$ 0
Zynerba Acquisition | Accrued compensation
Liabilities assumed
Accrued severance charges		7,544
Zynerba Acquisition | General and administrative expense
Liabilities assumed
Severance charges		3,858
Zynerba Acquisition | Research and development expense
Liabilities assumed
Severance charges		$ 3,686